Fertility and sterility · 2012
Cost-effectiveness of cytogenetic evaluation of products of conception in the patient with a second pregnancy loss.
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Foyouzi Nastaran, Cedars Marcelle I, Huddleston Heather G
Аннотация
OBJECTIVE: To compare the cost of two strategies for managing the patient with recurrent pregnancy loss (RPL).
DESIGN: Cost analysis using a decision analytic model was used to compare obtaining an evidence-based workup (EBW) for RPL versus obtaining a karyotype of the products of conception (POC) and proceeding with an EBW only in the setting of euploid POC.
SETTING: Outpatient care.
PATIENT(S): A simulated cohort of patients experiencing a second pregnancy loss.
INTERVENTION(S): Not applicable.
MAIN OUTCOME MEASURE(S): Total cost of investigating the cause of RPL after a second pregnancy loss.
RESULT(S): For all age categories, obtaining a karyotype of POC was less costly than an evidenced-based RPL evaluation. Monte Caro analysis demonstrated a net economic benefit for the karyotype strategy ($4,498 [±$792] vs. $5,022 [±$1,130]).
CONCLUSION(S): Our model suggests an economic advantage for obtaining a karyotype of POC in women with second miscarriage.
DESIGN: Cost analysis using a decision analytic model was used to compare obtaining an evidence-based workup (EBW) for RPL versus obtaining a karyotype of the products of conception (POC) and proceeding with an EBW only in the setting of euploid POC.
SETTING: Outpatient care.
PATIENT(S): A simulated cohort of patients experiencing a second pregnancy loss.
INTERVENTION(S): Not applicable.
MAIN OUTCOME MEASURE(S): Total cost of investigating the cause of RPL after a second pregnancy loss.
RESULT(S): For all age categories, obtaining a karyotype of POC was less costly than an evidenced-based RPL evaluation. Monte Caro analysis demonstrated a net economic benefit for the karyotype strategy ($4,498 [±$792] vs. $5,022 [±$1,130]).
CONCLUSION(S): Our model suggests an economic advantage for obtaining a karyotype of POC in women with second miscarriage.